Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 141 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Hepatic Function Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693
View directory record Official record
Conditions
Healthy Volunteer, Hepatic Impairment
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT07342868
View directory record Official record
Conditions
Chronic Hepatitis B Infections
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

NCT03627754
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Glasdegib 100 mg single oral dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

NCT00118170
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

NCT04190654
View directory record Official record
Conditions
Hepatic Impairment
Interventions
KW-6356
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

NCT01563562
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT01429337
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Midostaurin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function

NCT00275093
View directory record Official record
Conditions
Hepatic Complications, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Acute Effect of Exenatide on Brain Glucose Metabolism

NCT01588418
View directory record Official record
Conditions
Impaired Glucose Tolerance (IGT), Diabetes
Interventions
Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions
TVB-2640 - 50 mg
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

NCT01319279
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Hydrocodone bitartrate extended-release tablet
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 24, 2026, 10:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

NCT06997276
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
Mirdametinib (MEK Inhibitor)
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

NCT05674474
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Vorasidenib
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616
View directory record Official record
Conditions
Hepatic Impairment (HI)
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

NCT02611505
View directory record Official record
Conditions
Hepatic Impairment, Normal Hepatic Function
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

NCT05098054
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 24, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

NCT04241835
View directory record Official record
Conditions
Hepatic Impairment, Advanced Malignant Solid Tumor
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Lake Mary, Florida • Chicago, Illinois • Royal Oak, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

NCT02388620
View directory record Official record
Conditions
Normal Hepatic Function, Impaired Hepatic Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Anaheim, California • Coral Gables, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227
View directory record Official record
Conditions
Liver Disease, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 24, 2026, 10:27 AM EDT